IMCB Visiting Professor Laboratory is a partnership between the Centre for Cancer Biology (CCB) and the Institute of Molecular and Cell Biology (IMCB) in Singapore.
Professor's Vinay Tergaonkar laboratory extensively collaborates with CCB scientists on a range of projects including diabetes and metabolism, Mast cell biology and role of post translational modifications in cancer
Prof Vinay Tergaonkar obtained his Ph.D. (2001), from National Center for Biological Sciences, Bangalore. During his graduate studies he was awarded an international cancer society (UICC) fellowship for collaborative research at Tufts University, Boston, USA.
He has been a fellow (2001-2004) and a special fellow (2004-present) of the Leukemia and Lymphoma Society of America and conducted his postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California.
He is currently a research director at Institute for Molecular and Cell Biology in Singapore and is adjunct Professor at Department of Biochemistry, National University of Singapore.
He serves on Editorial Boards of:
He has received international recognition for his work including the British council development award (2014) and the Premier's fellowship from Government of South Australia (2015).
Inflammation is the normal response to infections in every person. But, if allowed to persist unchecked inflammation is, paradoxically, a potent stimuli of many human ailments, including autoimmune disorders, neurodegenerative diseases, metabolic syndromes (including diabetes) and cancer. Cancers are a perfect illustration, firstly by evading and then hijacking the innate and adaptive immune systems in its progression to a life-threatening disease.
Our team is deciphering how this immune system hijacking is accomplished by cancer cells at the genetic level. To achieve this, we use the highest sensitivity protein and next-generation RNA profiling techniques to analyse key mediators of these processes in a variety of ailments effecting millions of Australians. Identifying these genetic Trojan horses will allow us to design new, highly-specific and highly-effective targeted therapies to treat patients at all stages of their disease.
Current research projects